NCT00986284
Suspended
Phase 2
Phase II Study of EGFR Status Based Gefitinib Neoadjuvant Therapy in NSCLC Patients
Tianjin Medical University Cancer Institute and Hospital1 site in 1 country102 target enrollmentSeptember 2009
Overview
- Phase
- Phase 2
- Intervention
- gefitinib
- Conditions
- Non Small Cell Lung Cancer
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Enrollment
- 102
- Locations
- 1
- Primary Endpoint
- Response Rate
- Status
- Suspended
- Last Updated
- 10 years ago
Overview
Brief Summary
This study aims to investigate the efficacy and safety of gefitinib as neoadjuvant therapy in stage IIIA NSCLC patients.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients pathological diagnosed with NSCLC,with EGFR sensitive mutation;
- •Stage IIIA patients with technical operable disease evaluated by image and lab results;
- •Patients without chemotherapy or targeted-therapy before;
- •Inform Consent.
Exclusion Criteria
- •Patients with malignant tumor other than lung cancer;
- •Patients with other diseases such as cardiovascular disease that may hamper follow up;
- •Patients that may not coordinate well,judged by researcher.
Arms & Interventions
Gefitinib, Neoadjuvant therapy
Patients with EGFR mutation will be recruited and treated with gefitinib.
Intervention: gefitinib
Outcomes
Primary Outcomes
Response Rate
Time Frame: 1 month
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Phase II study of gefitinib in patients with EGFR mutation positive- advanced non-small cell lung cancernon-small cell lung cancerJPRN-C000000151West Japan Oncology Group25
Completed
Phase 2
PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker DiscoveryNon-small Cell Lung CancerNCT02804776National Cancer Centre, Singapore15
Completed
Phase 2
Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid TumorsSolid TumorNCT02447419Samsung Medical Center16
Completed
Phase 2
A Phase II study of Gefitinib as First-Line Treatment for Elderly Patients with Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations.on-Small-Cell Lung CancerJPRN-UMIN000001863Central Japan Lung Study Group19
Unknown
Not Applicable
PhaseII stady of gefitinib and in patients with relapsed advanced non-small cell lung cancerJPRN-C000000142Department of Medical Oncology Kinki University School of Medicine30